U69-CART cells for relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of cell therapy (U69-CART cells) that targets a specific protein (CCR9) found on leukemia cells in people whose T-cell acute lymphoblastic leukemia or lymphoma has come back or hasn't responded to standard treatments. The goal is to see if this therapy can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 15 and 75 years old.
- You must have T-cell acute lymphoblastic leukemia or lymphoma that has returned or hasn't responded to at least two prior treatments.
- Your leukemia cells must have a specific marker called CCR9 (confirmed by a lab test).
- You must be in generally good health (able to do daily activities with little help, and major organs like heart, lungs, liver, and kidneys must be working well).
- You cannot have had certain prior treatments (like other cell therapies targeting CCR9, certain antibodies, or live vaccines) within specific time frames.
- You must not have active infections, other cancers, or central nervous system disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy (called ssCART-19) for people with B-cell lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells to target and kill cancer cells.
This trial tests whether a new immune therapy (CAR-T cells) can treat certain types of blood cancers that have come back or not responded to standard treatments. It aims to help people with aggressive B-cell lymphoma or acute lymphoblastic leukemia (ALL) that hasn't been controlled by other therapies.
This trial tests a type of immunotherapy called CAR-T cells that are made from your own blood cells and are designed to find and destroy leukemia cells. It is for patients whose leukemia has come back or hasn't gone away after other treatments.
This trial tests a new CAR-T cell therapy for children, teens, and young adults with acute lymphoblastic leukemia that has not responded to standard treatment. The goal is to see if the therapy can put the leukemia into remission so the patient may then have a stem cell transplant.
This trial tests a new type of cell therapy (CAR T) that targets two markers on lymphoma cells, CD19 and CD22. It is for people with aggressive B-cell lymphoma that has not responded to standard treatments.
This trial tests a new CAR T-cell therapy called MB-CART2219.1 in people with certain types of blood cancer (like lymphoma or leukemia) that have come back or not responded to other treatments. CAR T-cells are your own immune cells that are modified to better find and kill cancer cells.
Hear when a new Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.